Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ozuriftamab Vedotin · BA-3021

Antibody-drug conjugate · Kills target cells, directed at receptor tyrosine kinase-like orphan receptor 2 (ROR2) · developed by BioAtla

Phase 2 Most advanced trial
1 Registered trials

What is Ozuriftamab Vedotin?

Ozuriftamab vedotin is an antibody-drug conjugate made of ozuriftamab, a conditionally active antibody against ROR2, linked to monomethyl auristatin E. The antibody becomes active only under the conditions of the tumor microenvironment, binds ROR2-expressing cancer cells, and is internalized to deliver the cytotoxic payload. It is being studied in ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BA-3021
Drug type
Antibody-drug conjugate
Targets
receptor tyrosine kinase-like orphan receptor 2 (ROR2)
Mechanism
Kills target cells, directed at receptor tyrosine kinase-like orphan receptor 2 (ROR2)
Pathways
Wnt signal transduction
Therapy area
Oncology
Developer
BioAtla, Inc.
In trials of
AZN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
BPM6YN0KLI

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04918186 Phase 2 Ovarian Cancer Recruiting AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian Cancer

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.